Tissue Regenix Group Regulatory News (TRX)

Tissue Regenix Group plc

DermaPure® Medicare coverage in further 10 States

Leeds, 1st September 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces that effective from today it has gained Medicare coverage in an additional 10 States covered by Medicare jurisdiction National Government Services (NGS) for the use of DermaPure®.

NGS, whose jurisdiction covers Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont and Wisconsin, has taken the decision to retire their local coverage determination (LCD) for cellular and tissue based products allowing for DermaPure® to be eligible for Medicare reimbursement in outpatient settings across these states. This new coverage adds an additional 7.5 million Medicare beneficiaries and means that Tissue Regenix has now secured Medicare reimbursement in 47 States, totalling 93% of traditional Medicare beneficiaries.

DermaPure® utilises Tissue Regenix's patented dCELL® Technology allowing for a regenerative approach to wound healing and has multiple applications in the treatment of chronic and acute wounds such as diabetic foot ulcers, venous leg ulcers, surgical and trauma wounds.

Patti Gary, VP Clinical Affairs Tissue Regenix Wound Care, Inc. said "We welcome the decision by NGS to retire their LCD allowing for the use of clinically advanced and novel wound care products, which will ultimately benefit the treatment and recovery of patients. We are delighted that DermaPure® now has Medicare coverage in 47 States allowing physicians to access and employ our unique dCELL® Technology which has the potential to offer superior clinical and economic outcomes."

For more Information:

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

 In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.